Literature DB >> 14754420

Alpha-galactosylceramide: potential immunomodulatory activity and future application.

Yoshihiro Hayakawa1, Dale I Godfrey, Mark J Smyth.   

Abstract

alpha-Galactosylceramide (alpha-GalCer), is a glycolipid which has been identified as a ligand recognized by a special group of immune T cells, known as invariant NKT cells. alpha-GalCer can powerfully activate invariant NKT cells to produce immunoregulatory cytokines, including interferon-gamma and IL-4, and thereby exert a variety of subsequent effects on other cells in the immune system. Recent studies have revealed the mechanism of alpha-GalCer-induced iNKT cell-activation in immune responses to tumors and microbes, and in the suppression of autoimmune diseases. In this review, we discuss the potential immunomodulatory activity of alpha-GalCer and its possible future application for clinical studies in humans.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14754420     DOI: 10.2174/0929867043456115

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  19 in total

Review 1.  Going both ways: immune regulation via CD1d-dependent NKT cells.

Authors:  Dale I Godfrey; Mitchell Kronenberg
Journal:  J Clin Invest       Date:  2004-11       Impact factor: 14.808

2.  NKT cell stimulation with glycolipid antigen in vivo: costimulation-dependent expansion, Bim-dependent contraction, and hyporesponsiveness to further antigenic challenge.

Authors:  Adam P Uldrich; Nadine Y Crowe; Konstantinos Kyparissoudis; Daniel G Pellicci; Yifan Zhan; Andrew M Lew; Philippe Bouillet; Andreas Strasser; Mark J Smyth; Dale I Godfrey
Journal:  J Immunol       Date:  2005-09-01       Impact factor: 5.422

3.  Type II NKT cells facilitate Alum-sensing and humoral immunity.

Authors:  Hemangi B Shah; T Scott Devera; Pragya Rampuria; Gillian A Lang; Mark L Lang
Journal:  J Leukoc Biol       Date:  2012-07-13       Impact factor: 4.962

4.  Design, Synthesis, and Immunological Evaluation of Benzyloxyalkyl-Substituted 1,2,3-Triazolyl α-GalCer Analogues.

Authors:  Yogesh Kumar Verma; Bonam Srinivasa Reddy; Mithun S Pawar; Debabrata Bhunia; Halmuthur M Sampath Kumar
Journal:  ACS Med Chem Lett       Date:  2015-12-10       Impact factor: 4.345

5.  Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies.

Authors:  Ailsa J Christiansen; Alison West; Kellie-Marie Banks; Nicole M Haynes; Michele W Teng; Mark J Smyth; Ricky W Johnstone
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-22       Impact factor: 11.205

Review 6.  NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic malignancies.

Authors:  Edwin P Alyea; Daniel J DeAngelo; Jeffrey Moldrem; John M Pagel; Donna Przepiorka; Michel Sadelin; James W Young; Sergio Giralt; Michael Bishop; Stan Riddell
Journal:  Biol Blood Marrow Transplant       Date:  2010-05-24       Impact factor: 5.742

7.  Type I natural killer T cells suppress tumors caused by p53 loss in mice.

Authors:  Jeremy B Swann; Adam P Uldrich; Serani van Dommelen; Janelle Sharkey; William K Murray; Dale I Godfrey; Mark J Smyth
Journal:  Blood       Date:  2009-02-20       Impact factor: 22.113

8.  Invariant natural killer T cells regulate breast cancer response to radiation and CTLA-4 blockade.

Authors:  Karsten A Pilones; Noriko Kawashima; Anne Marie Yang; James S Babb; Silvia C Formenti; Sandra Demaria
Journal:  Clin Cancer Res       Date:  2009-01-15       Impact factor: 12.531

Review 9.  Cross-regulation between distinct natural killer T cell subsets influences immune response to self and foreign antigens.

Authors:  Philomena Arrenberg; Ramesh Halder; Vipin Kumar
Journal:  J Cell Physiol       Date:  2009-02       Impact factor: 6.384

Review 10.  Glycolipids as immunostimulating agents.

Authors:  Douglass Wu; Masakazu Fujio; Chi-Huey Wong
Journal:  Bioorg Med Chem       Date:  2007-10-13       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.